Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer
Status:
Recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm study to investigate the efficacy and safety of AK104 (an
Anti-PD1 and Anti-CTLA4 Bispecific Antibody) and neoadjuvant chemoradiotherapy in patients
with pMMR/MSS locally advanced rectal cancer.